GlassScriptPhysician profile
Muhammad Majeed
NPI 1114448016
$7,095.75
in general payments reported to CMS, 2019-2025
19 companies · $3,521 in 2025
The $3,521 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2022: $212 · 2023: $728 · 2024: $2,513 · 2025: $3,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,593 · Travel and Lodging: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,593.45 |
| Travel and Lodging | $2,169.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,421.34 | 2024-2025 | Orise, Spyglass, Exalt Model D |
| Abbvie INC. | $1,112.16 | 2023-2025 | |
| Medtronic, INC. | $401.17 | 2023-2025 | Manoscan, Nexpowder, Endoflip |
| Janssen Scientific Affairs, LLC | $336.81 | 2024-2025 | Stelara, Remicade, Tremfya |
| Genzyme Corporation | $329.31 | 2023-2025 | |
| Gilead Sciences, INC. | $313.73 | 2022-2023 | Vemlidy, Epclusa |
| Steris Corporation | $235.82 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $178.38 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $173.96 | 2023-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $130.83 | 2022-2025 | |
| Qol Medical, LLC | $121.55 | 2020 | |
| Ardelyx, INC. | $90.50 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $79.91 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $71.73 | 2024 | Voquezna |
| Pentax of America, INC. | $28.50 | 2024 | Pentax Medical, C2 Cryoballoon, Inspira |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.56 | 2024 | Zeposia |
| Evoke Pharma, INC. | $19.55 | 2023 | Gimoti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.33 | 2023 | Xifaxan |
| Cook Medical LLC | $14.61 | 2023 | Fusion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Majeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.